# THERAVANCE BIOPHARMA ENTERS INTO DEFINITIVE AGREEMENT TO BE ACQUIRED BY ZYMEWORKS FOR $17.00 PER SHARE IN CASH PLUS A CONTINGENT VALUE RIGHT
Canonical URL: https://biopharmsignal.com/news/TBPH/theravance-biopharma-enters-into-definitive-agreement-to-be-acquired-by-zymework-7bcac832
Ticker: TBPH
Company: Theravance Biopharma
Source: Theravance Biopharma
Published: 2026-06-29 10:00 EST
Original Source URL: https://investor.theravance.com/news-releases/news-release-details/theravance-biopharma-enters-definitive-agreement-be-acquired
## Summary

Theravance Biopharma shareholders to receive $17.00 per share in cash, representing an equity value of approximately $929 million Theravance Biopharma shareholders to receive a contingent value right (CVR) entitling them to 80% of net proceeds from any future license, divestiture or other

## Article Body
Theravance Biopharma shareholders to receive $17.00 per share in cash, representing an equity value of approximately $929 million Theravance Biopharma shareholders to receive a contingent value right (CVR) entitling them to 80% of net proceeds from any future license, divestiture or other
## Recent Company News
- 2026-06-29 10:00 EST — [THERAVANCE BIOPHARMA ENTERS INTO DEFINITIVE AGREEMENT TO BE ACQUIRED BY ZYMEWORKS FOR $17.00 PER SHARE IN CASH PLUS A CONTINGENT VALUE RIGHT](https://biopharmsignal.com/news/TBPH/theravance-biopharma-enters-into-definitive-agreement-to-be-acquired-by-zymework-7bcac832) — Source: Theravance Biopharma
- 2026-06-25 13:46 EST — [Theravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/TBPH/theravance-biopharma-inc-reports-first-quarter-2026-financial-results-and-provides-corporate-update) — Source: Theravance Biopharma
- 2026-06-25 13:46 EST — [Theravance Biopharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference](https://biopharmsignal.com/news/TBPH/theravance-biopharma-to-present-at-the-h-c-wainwright-27th-annual-global-investment-conference) — Source: Theravance Biopharma
- 2026-06-25 13:46 EST — [Theravance Biopharma to Present New Analyses Highlighting YUPELRI® (revefenacin) Outcomes in COPD at the 2025 CHEST Annual Meeting](https://biopharmsignal.com/news/TBPH/theravance-biopharma-to-present-new-analyses-highlighting-yupelrir-revefenacin-outcomes-in-copd-at-the-2025-chest-annual-meeting) — Source: Theravance Biopharma
- 2026-06-25 13:46 EST — [Theravance Biopharma Launches Disease Education Campaign to Advance Scientific Understanding of Neurogenic Orthostatic Hypotension Due to Multiple System Atrophy](https://biopharmsignal.com/news/TBPH/theravance-biopharma-launches-disease-education-campaign-to-advance-scientific-understanding-of-neurogenic-orthostatic-hypotension-due-to-multiple-system-atrophy) — Source: Theravance Biopharma
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)